RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Targeting immune microenvironment in cervical cancer: current research and advances.
Targeting immune microenvironment in cervical cancer: current research and advances.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫微环境在宫颈癌发病机制和治疗应答中发挥关键作用。本综述全面考察宫颈癌肿瘤免疫微环境(TIME)的细胞和分子组成,包括免疫细胞浸润模式(T细胞、B细胞、NK细胞、树突状细胞、TAM)、免疫检查点分子以及细胞因子/趋化因子网络。我们重点介绍对TIME异质性认识的最新进展,这些进展得益于高分辨率空间定位和单细胞测序技术,并特别关注不同疾病分期和治疗方案之间的差异。综述系统评估了免疫检查点抑制剂、过继性细胞疗法和治疗性疫苗等免疫治疗策略,讨论其作用机制、临床疗效和面临的挑战。通过综合临床前和临床研究的见解,本文旨在从转化研究角度探讨如何靶向TIME以改善宫颈癌患者的治疗结局。
The immune microenvironment plays a critical role in pathogenesis and treatment response of cervical cancer. This review comprehensively examines the cellular and molecular components of the tumor immune microenvironment (TIME) in cervical cancer, encompassing patterns of immune cell infiltration (T cells, B cells, NK cells, DCs, TAMs), immune checkpoint molecules, and cytokine/chemokine networks.
We emphasize recent advances in understanding TIME heterogeneity, enabled by high-resolution spatial mapping and single-cell sequencing technologies, focusing specifically on differences across disease stages and treatment approaches.
The review systematically evaluates immunotherapeutic strategies, such as immune checkpoint inhibitors, adoptive cell therapies, and therapeutic vaccines, discussing their mechanisms of action, clinical efficacy, and challenges. By synthesizing insights from both preclinical and clinical studies, our aim is to offer a translational perspective on targeting the TIME to enhance outcomes for cervical cancer patients.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。